Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/27/2025

Management of Atrial Flutter

Acute Management

  • The American Heart Association recommends beta blockers, diltiazem, or verapamil as first-line agents for acute rate control in hemodynamically stable patients with atrial flutter 1, 3
  • In patients with systolic heart failure where beta blockers are contraindicated or ineffective, intravenous amiodarone can be used for acute rate control 1
  • Higher doses of rate control medications are often needed in atrial flutter compared to atrial fibrillation due to paradoxically faster AV nodal conduction 2
  • The American College of Cardiology recommends avoiding beta blockers, diltiazem, and verapamil in patients with pre-excited atrial flutter due to risk of accelerated ventricular rates and ventricular fibrillation 2
  • Synchronized cardioversion is recommended for hemodynamically unstable patients 3
  • Elective synchronized cardioversion is indicated in stable patients when pursuing rhythm control 3, 4
  • Intravenous ibutilide is effective for acute pharmacological cardioversion 5
  • Rapid atrial pacing is useful for acute conversion in patients with pacing wires already in place 3

Anticoagulation

  • Anticoagulation recommendations for atrial flutter are the same as for atrial fibrillation 1, 2, 3
  • For flutter lasting <48 hours in low-risk patients, anticoagulation should be started before or immediately after cardioversion 4
  • For flutter lasting ≥48 hours or unknown duration, anticoagulation should be given for at least 3 weeks before cardioversion or a transesophageal echocardiogram should be performed to exclude thrombus 6
  • Following cardioversion, anticoagulation should be continued for at least 4 weeks 4, 6
  • Long-term anticoagulation decisions should be based on the patient's thromboembolic risk profile using the same criteria as for atrial fibrillation 2, 3

Long-term Management

  • Catheter ablation of the CTI is highly effective (>90% success rate) for typical atrial flutter and is the preferred long-term management strategy 1, 5
  • The European Society of Cardiology recommends catheter ablation for recurrent symptomatic non-CTI-dependent flutter after failure of at least one antiarrhythmic drug 2
  • Catheter ablation is reasonable as primary therapy for recurrent symptomatic non-CTI-dependent flutter before trials of antiarrhythmic drugs 5
  • If catheter ablation is not an option, amiodarone, dofetilide, and sotalol can be useful to maintain sinus rhythm 2, 5
  • Flecainide or propafenone may be considered in patients without structural heart disease 5

Special Considerations

  • The American College of Cardiology recommends avoiding AV nodal blocking agents in patients with pre-excited atrial flutter 7, 8
  • Direct current cardioversion is recommended for patients with pre-excitation and hemodynamic instability 4
  • The risk of stroke in patients with atrial flutter is similar to that in atrial fibrillation, with thromboembolism rates averaging 3% annually 1
  • Meta-analysis of 13 studies reported short-term stroke risks ranging from 0% to 7% in patients undergoing cardioversion of atrial flutter 1

Common Pitfalls and Caveats

  • Rate control can be more difficult to achieve in atrial flutter than in atrial fibrillation 2
  • Conversion of atrial flutter to atrial fibrillation may occur with antiarrhythmic drugs 1
  • When using class IC antiarrhythmic drugs for rhythm control, concomitant AV nodal blocking drugs should be administered to prevent rapid ventricular rates if flutter occurs 7

REFERENCES